Preferred Label : Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010;
NCIt synonyms : Allogeneic CRISPR-edited CD19-targeted CAR T Cells CB-010; Allogeneic CRISPR-edited Anti-CD19 CAR T-cells CB-010;
NCIt definition : A preparation of allogeneic, off-the-shelf T-lymphocytes genetically modified to express
a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA)
CD19, and clustered regularly interspaced short palindromic repeats (CRISPR)-edited
to eliminate endogenous T-cell receptor (TCR) and programmed death 1 (PD-1; PDCD1;
CD279; programmed cell death-1) expression, with potential immunostimulating and antineoplastic
activities. Upon administration, the allogeneic CRISPR-edited anti-CD19 CAR-T cells
CB-010 recognize and bind to CD19-expressing tumor cells. This may result in a specific
cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. PD-1,
an immune checkpoint receptor expressed on T-cells, plays a key role in tumor immune
evasion by binding to its ligand programmed death ligand 1 (PD-L1; cluster of differentiation
274; CD274; programmed cell death-1 ligand 1) expressed on tumor cells. By removing
PD-1 from T-cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion
and may enhance T-cell activity against the CD19-expressing tumor cells. The endogenous
TCR is removed to prevent graft-versus-host disease (GvHD). CD19 antigen is a B-cell
specific cell surface antigen overexpressed in B-cell lineage malignancies.;
Molecule name : CB-010; CB 010;
NCI Metathesaurus CUI : CL1661920;
Origin ID : C179255;
UMLS CUI : C5555556;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
